Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 425.00 thousand shares for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-12-31 was 0.00 shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-09-30 was 0.00 shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-09-30 was 0.00 shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 425.00K shares, a 42.62% increase from fiscal 2014.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 298.00K shares, a 27.32% decline from fiscal 2013.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 410.00K shares, a 52.98% decline from fiscal 2012.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2012 was 872.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | 0.00 shares derived: sum of 2 quarters · filed 2017-09-25 | 425.00K shares 10-K · filed 2017-09-25 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | 425.00K shares 10-Q · filed 2015-12-01 | ||
| 2015-06-30 | 425.00K shares 10-Q · filed 2015-08-19 | |||
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | 0.00 shares derived: sum of 2 quarters · filed 2017-06-19 | 114.00K shares derived: sum of 3 quarters · filed 2017-06-19 | 298.00K shares 10-K · filed 2017-06-19 |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | 114.00K shares derived: sum of 2 quarters · filed 2014-11-13 | 298.00K shares 10-Q · filed 2014-11-13 | 698.00K shares derived: sum of 4 quarters · filed 2015-04-14 |
| 2014-06-30 | 114.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-19 | 298.00K shares 10-Q · filed 2014-08-19 | 698.00K shares derived: sum of 3 quarters · filed 2015-04-14 | 698.00K shares derived: sum of 4 quarters · filed 2015-04-14 |
| 2014-03-31 | 184.00K shares 10-Q · filed 2014-05-14 | 584.00K shares derived: sum of 2 quarters · filed 2015-04-14 | 584.00K shares derived: sum of 3 quarters · filed 2015-04-14 | |
| 2013-12-31 | 400.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | 400.00K shares derived: sum of 2 quarters · filed 2015-04-14 | 410.00K shares 10-K · filed 2015-04-14 | |
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-08 | 10.00K shares 10-Q · filed 2013-11-08 | ||
| 2013-06-30 | 10.00K shares 10-Q/A · filed 2013-09-06 | |||
| 2012-12-31 | 872.00K shares 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |